Recent reports have shown that in breast and other cancer models, treatment with low doses of doxorubicin resulted in increased expression of TRAIL receptors, (i.e. DR4 and DR5) [6], [8], [31]. The gene discussed is TNFRSF10A; the disease is cancer.